Biomarkers of Uremic Cardiotoxicity

Stopić, Bojan; Dragičević, Sandra; Medić, Branislava; Nikolić, Aleksandra; Stojanović, Marko; Budisavljevic, Sreten; Dimković, Nada

doi:10.3390/toxins13090639

Cited by 3 publications

(3 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, there is still room for new research that would allow us to timely and efficiently prevent CV disease in CKD patients thus improving their survival. 86…”

Section: Discussionmentioning

confidence: 99%

Biomarkers and Predictors of Adverse Cardiovascular Events in Different Stages of Chronic Kidney Disease

et al. 2022

Self Cite

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is an important factor that contributes to the increase of all-cause morbidity and mortality in the group of non-communicable diseases, and it is also recognized as a strong and independent risk factor that contributes to cardiovascular disease (CVD). CVDs are a consequence of the action of a large number of risk factors among which are traditional and non-traditional. These risk factors have been the subject of a large number of studies which partially explained the unfavorable cardiovascular (CV) outcome of CKD patients. Therefore, valid studies about clinical and biohumoral predictors are of particular importance, especially in the early stages of renal disease, that is, in patients with creatinine clearance below 60 ml/min/1.73 m2 when preventive measures are most effective. Among potential predictors of adverse CV outcome are biomarkers of inflammation (Interleukin-18—IL-18), oxidative stress (ischemia-modified albumin—IMA; superoxide dismutase—SOD), acute kidney injury (kidney injury molecule -1—KIM-1; neutrophil gelatinase–associated lipocalin—NGAL), and microribonucleic acids (specific microRNA-133a). In this review, we tried to confirm the relationship between risk factors of CKD and CVD and newer, less frequently examined biomarkers with the occurrence of incidental CV events in renal patients.

show abstract

“…Therefore, there is still room for new research that would allow us to timely and efficiently prevent CV disease in CKD patients thus improving their survival. 86…”

Section: Discussionmentioning

confidence: 99%

Biomarkers and Predictors of Adverse Cardiovascular Events in Different Stages of Chronic Kidney Disease

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similarly, our results show that the risk of CV events increased alongside the decline in eGFR, which aligns with the current consensus. Furthermore, most of the studies [20,[28][29][30] in the literature indicate that hypoalbuminemia is associated with adverse kidney and CV outcomes. Our outcomes also indicate the same phenomenon, which support the importance of routinely testing serum albumin.…”

Section: Discussionmentioning

confidence: 99%

Development and Validation of a Cardiovascular Disease Risk Prediction Model for Patients with Non-Dialysis-Dependent Chronic Kidney Diseases Based on the Nomogram

Wang

Yang

et al. 2022

Kidney Blood Press Res

View full text Add to dashboard Cite

Introduction Most CKD patients experience cardiovascular issues before commencing renal replacement therapy. An accuracy prediction model is helpful for physicians to assess cardiovascular prognoses in each individual, and to provide insights on how to outline individualized lines of therapy. Method This study enrolled 1138 participants with non-dialysis-dependent chronic kidney disease (NDD-CKD). Following a proportion of 7:3, patients were randomly assigned to training and validation cohorts. The relevant predictors of cardiovascular events were screened using the least absolute shrinkage and selection operator (Lasso) regression. The area under the receiver operating characteristic curve (AUC) and the calibration curve with 1000 bootstraps resamples were used to assess the nomogram's performance. Tests on the discrimination of the prediction model used Kaplan-Meier (KM) curve. Results After screening all the predictors by lasso regression, the five remaining ones (albumin, estimated glomerular filtration rate, etiology of CKD, cardiovascular disease history, and age) were used to construct the prediction model. The AUC of 1-year, 2-year, and 3-year was 0.81 (95% CI = 0.75–0.87), 0.80 (95% CI = 0.75–0.86), and 0.80 (95% CI = 0.73–0.86), respectively. The calibration curve and the KM curve showed good prediction features, and the external validation also had a good prediction performance (AUC of 1-, 2-, and 3-years were 0.77, 0.84, and 0.82, respectively). Conclusion We successfully developed a novel nomogram that has decent prediction performance and can be used for assessing the probability of cardiovascular events in patients with NDD-CKD, displaying valuable potential for clinical application.

show abstract

“…miR-133a was also analyzed in another prospective cohort study of 87 patients with CKD of various degrees [ 74 ]. Despite miR-133a levels being altered in these patients, no correlations were found with the entity of LVH or with the occurrence of a composite endpoint of CV death or CV events over an 18-month follow-up.…”

Section: Clinical Studies Of Mirnas In Ckd/eskd Individualsmentioning

confidence: 99%

miRNAs in Uremic Cardiomyopathy: A Comprehensive Review

D'Agostino

Mauro

Zicarelli

et al. 2023

IJMS

View full text Add to dashboard Cite

Uremic Cardiomyopathy (UCM) is an irreversible cardiovascular complication that is highly pervasive among chronic kidney disease (CKD) patients, particularly in End-Stage Kidney Disease (ESKD) individuals undergoing chronic dialysis. Features of UCM are an abnormal myocardial fibrosis, an asymmetric ventricular hypertrophy with subsequent diastolic dysfunction and a complex and multifactorial pathogenesis where underlying biological mechanisms remain partly undefined. In this paper, we reviewed the key evidence available on the biological and clinical significance of micro-RNAs (miRNAs) in UCM. miRNAs are short, noncoding RNA molecules with regulatory functions that play a pivotal role in myriad basic cellular processes, such as cell growth and differentiation. Deranged miRNAs expression has already been observed in various diseases, and their capacity to modulate cardiac remodeling and fibrosis under either physiological or pathological conditions is well acknowledged. In the context of UCM, robust experimental evidence confirms a close involvement of some miRNAs in the key pathways that are known to trigger or worsen ventricular hypertrophy or fibrosis. Moreover, very preliminary findings may set the stage for therapeutic interventions targeting specific miRNAs for ameliorating heart damage. Finally, scant but promising clinical evidence may suggest a potential future application of circulating miRNAs as diagnostic or prognostic biomarkers for improving risk stratification in UCM as well.

show abstract

Biomarkers of Uremic Cardiotoxicity

Cited by 3 publications

References 58 publications

Biomarkers and Predictors of Adverse Cardiovascular Events in Different Stages of Chronic Kidney Disease

Biomarkers and Predictors of Adverse Cardiovascular Events in Different Stages of Chronic Kidney Disease

Development and Validation of a Cardiovascular Disease Risk Prediction Model for Patients with Non-Dialysis-Dependent Chronic Kidney Diseases Based on the Nomogram

miRNAs in Uremic Cardiomyopathy: A Comprehensive Review

Contact Info

Product

Resources

About